pI: 8.0373 |
Length (AA): 150 |
MW (Da): 17132 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
2 | 149 | 1jat (A) | 3 | 150 | 67.00 | 0 | 1 | 1.95937 | -2.11 |
3 | 114 | 2awf (A) | 2 | 131 | 37.00 | 0 | 1 | 1.26437 | -1.36 |
3 | 148 | 2r0j (A) | 2 | 147 | 63.00 | 0 | 1 | 1.89003 | -2.18 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_127739)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G16890 | ubiquitin-conjugating enzyme E2 36 |
Arabidopsis thaliana | AT1G78870 | ubiquitin-conjugating enzyme E2 35 |
Babesia bovis | BBOV_IV007110 | ubiquitin-conjugating enzyme E2, putative |
Brugia malayi | Bm1_32080 | ubiquitin conjugating enzyme protein 13 |
Brugia malayi | Bm1_31770 | Ubiquitin conjugating enzyme protein 13 |
Candida albicans | CaO19.2225 | ubiquitin-conjugating enzyme |
Candida albicans | CaO19.8548 | post-replication repair |
Candida albicans | CaO19.933 | ubiquitin conjugating enzyme |
Caenorhabditis elegans | CELE_Y54G2A.31 | Protein UBC-13 |
Cryptosporidium hominis | Chro.30262 | ubiquitin-conjugating enzyme |
Cryptosporidium parvum | cgd3_2220 | ubiquitin-conjugating enzyme |
Dictyostelium discoideum | DDB_G0277267 | hypothetical protein |
Drosophila melanogaster | Dmel_CG3473 | CG3473 gene product from transcript CG3473-RB |
Drosophila melanogaster | Dmel_CG18319 | bendless |
Echinococcus granulosus | EgrG_000334400 | ubiquitin conjugating enzyme E2 N |
Entamoeba histolytica | EHI_164400 | ubiquitin-conjugating enzyme family protein |
Echinococcus multilocularis | EmuJ_000334400 | ubiquitin conjugating enzyme E2 N |
Homo sapiens | 7334 | _UBC13, UbcH-ben, UbcH13 |
Leishmania braziliensis | LbrM.04.0880 | ubiquitin-conjugating enzyme e2, putative |
Leishmania donovani | LdBPK_040680.1 | ubiquitin-conjugating enzyme E2, putative |
Leishmania infantum | LinJ.04.0680 | ubiquitin-conjugating enzyme e2, putative |
Leishmania major | LmjF.04.0680 | ubiquitin-conjugating enzyme e2, putative |
Leishmania mexicana | LmxM.04.0680 | ubiquitin-conjugating enzyme e2, putative |
Loa Loa (eye worm) | LOAG_03706 | ubiquitin conjugating enzyme protein 13 |
Loa Loa (eye worm) | LOAG_08714 | ubiquitin conjugating enzyme protein 13 |
Mus musculus | 100041224 | predicted gene 3213 |
Mus musculus | ENSMUSG00000074781 | ubiquitin-conjugating enzyme E2N |
Mus musculus | 102642334 | ubiquitin-conjugating enzyme E2 N-like |
Neospora caninum | NCLIV_044380 | Ubiquitin carrier protein (EC 6.3.2.-), related |
Oryza sativa | 4325905 | Os01g0673600 |
Plasmodium berghei | PBANKA_1241900 | ubiquitin-conjugating enzyme E2 N, putative |
Plasmodium falciparum | PF3D7_0527100 | ubiquitin-conjugating enzyme E2 N, putative |
Plasmodium knowlesi | PKNH_1005600 | ubiquitin-conjugating enzyme E2 N, putative |
Plasmodium vivax | PVX_079885 | ubiquitin-conjugating enzyme E2 N, putative |
Saccharomyces cerevisiae | YDR092W | E2 ubiquitin-conjugating protein UBC13 |
Schistosoma japonicum | Sjp_0042100 | ko:K10580 ubiquitin-conjugating enzyme E2 N, putative |
Schistosoma mansoni | Smp_083400 | ubiquitin conjugating enzyme 13 |
Schmidtea mediterranea | mk4.006434.00 | |
Schmidtea mediterranea | mk4.019358.00 | Ubiquitin-conjugating enzyme E2 N |
Trypanosoma brucei gambiense | Tbg972.9.4360 | ubiquitin-conjugating enzyme e2, putative,ubiquitin carrier protein, putative,ubiquitin-protein ligase, putative |
Trypanosoma brucei | Tb927.9.8000 | ubiquitin-protein ligase, putative |
Trypanosoma congolense | TcIL3000_9_2750 | ubiquitin-protein ligase, putative |
Trypanosoma cruzi | TcCLB.453445.20 | ubiquitin-conjugating enzyme E2, putative |
Trypanosoma cruzi | TcCLB.508137.30 | ubiquitin-conjugating enzyme E2, putative |
Toxoplasma gondii | TGME49_304770 | ubiquitin-conjugating enzyme subfamily protein |
Theileria parva | TP01_0508 | ubiquitin-protein ligase, putative |
Trichomonas vaginalis | TVAG_154710 | ubiquitin-conjugating enzyme E2, putative |
Trichomonas vaginalis | TVAG_452760 | ubiquitin-conjugating enzyme E2, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb09.211.0050 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.211.0050 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb09.211.0050 this record | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb09.211.0050 this record | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_Y54G2A.31 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_Y54G2A.31 | Caenorhabditis elegans | slow growth | wormbase |
PBANKA_1241900 | Plasmodium berghei | Essential | plasmo |
TGME49_304770 | Toxoplasma gondii | Probably essential | sidik |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | _UBC13, UbcH-ben, UbcH13 | Compounds | References |
Influenza A virus | Neuraminidase | Compounds | References |
5 literature references were collected for this gene.